Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
Key facts
- Who runs it
- Glenn-Milo Santos
- Where
- San Francisco, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 60 people enrolled
- Started
- 14 Dec 2021
- Ended
- 1 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Naltrexone Hydrochloride
- Placebo
- Ecological Momentary Intervention
- Record updated
- 27 October 2025
Who can take part
- Age
- 18 years to 70 years
- Sex
- Men only
- Healthy volunteers
- Can take part
Show the full registry criteria (21)Hide the full registry criteria
Who can take part
- cisgender male (male gender and sex assigned at birth)
- age 18-70 years* (naltrexone's tolerability and safety has been demonstrated among older adults up to age 70)
- self-reported condomless anal sex with men or missing Pre-Exposure Prophylaxis or antiretroviral therapy doses due to meth use in the prior three months while under the influence of meth
- self-reported meth use at least weekly
- mild, moderate or severe meth use disorder
- positive meth sample via sweat patch or urine testing during screening
- interested in reducing meth use
- no current acute illness requiring prolonged medical care
- no chronic illness that is likely to progress clinically during trial
- able and willing to provide informed consent and adhere to visit schedule
- current CD4 count ≥ 200 cells/mm3; or CD4 count of 100-199 cells/mm3 and HIV viral load < 200 copies/mL (if living with HIV)
- baseline complete blood count, total protein, albumin, glucose, alkaline phosphatase, creatinine, blood urea nitrogen test, and electrolytes without clinically significant abnormalities as determined by study clinician in conjunction with symptoms, physical exam, and medical history
Who cannot take part
- known allergy or prior adverse reaction to naltrexone
- any psychiatric (e.g., depression with suicidal ideation) or medical condition that would preclude safe participation
- current use of any opioids or a known medical condition which currently requires or may likely require opioid analgesics
- severe alcohol use disorder as determined by structured clinical interview for DSM-5 criteria
- any condition that, in the PI and/or study clinician's judgment interferes with safe participation or adherence to study procedures
- moderate or severe liver disease (aspartate aminotransferase test, alanine aminotransferase test, or total bilirubin > 3 times upper limit of normal)
- impaired renal function (creatinine clearance < 60 ml/min)
- opioid-positive urine test at screen/enrollment visits (naltrexone can induce opioid withdrawal)
- currently participating in another intervention research study with potential overlap
Where in United States
- San Francisco Department of Public HealthSan Francisco, United States
About the trial
What the trial wants to find out
This is a double-blind, placebo-controlled phase 2b trial in which 54 MSM who use meth will be randomly assigned (2:1) to receive 12 weeks of as-needed intermittent oral naltrexone 50 mg enhanced with an EMA-informed EMI platform, or receive as-needed placebo with EMA-informed EMI. The 12-week treatment period is consistent with other pharmacotherapy trials for substance use disorders. The proposed sample size is also consistent with other phase 2b trials for substance use treatment. Upon enrollment, participants will complete daily EMA assessments and weekly visits for behavioral surveys and urine testing for meth metabolites, study drug dispensing and computer-based counseling for substance use. Safety laboratory assessments and vital signs will be completed monthly. Efficacy (Specific Aims 1-3) will be assessed upon trial completion as measured by proportion meth-positive urine samples; PrEP and ART adherence by drug levels and viral load testing; and sexual risk behavior data accounting for PrEP use and viral suppression.
The 2 groups in the trial
- Naltrexone with ecological momentary interventionTreatment being tested
Naltrexone Hydrochloride, 50 mg., intermittent with ecological momentary assessment (EMA)
Treatment: Naltrexone Hydrochloride and Ecological Momentary Intervention
- Placebo with ecological momentary interventionPlacebo, for comparison
Placebo, intermittent with ecological momentary assessment (EMA)
Treatment: Placebo and Ecological Momentary Intervention
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The ION+EMI Study: Intermittent Oral Naltrexone Enhanced With an Ecological Momentary Intervention for Methamphetamine-using MSM
- Record updated
- 27 October 2025